Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validity of identification algorithms combining diagnostic codes with other measures for acute ischemic stroke in MID-NET®.
Tanigawa M, Kohama M, Nonaka T, Saito A, Tamiya A, Nomura H, Kataoka Y, Okauchi M, Tamiya T, Inoue R, Nakayama M, Suzuki T, Uyama Y, Yokoi H. Tanigawa M, et al. Among authors: tamiya t, tamiya a. Pharmacoepidemiol Drug Saf. 2022 May;31(5):524-533. doi: 10.1002/pds.5423. Epub 2022 Mar 9. Pharmacoepidemiol Drug Saf. 2022. PMID: 35224801
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA.
Taniguchi Y, Tamiya A, Osuga M, Isa SI, Nakamura K, Mizumori Y, Shinohara T, Yanai H, Nakatomi K, Oki M, Mori M, Kuwako T, Yamazaki K, Shimada M, Ando M, Koh Y. Taniguchi Y, et al. Among authors: tamiya a. Invest New Drugs. 2025 Jan 9. doi: 10.1007/s10637-024-01500-9. Online ahead of print. Invest New Drugs. 2025. PMID: 39789369
YAP regulates HER3 signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancer.
Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, Hirai S, Nakamura R, Morimoto K, Furuya N, Arai S, Goto Y, Sakata Y, Nishino K, Tsuchiya M, Tamiya A, Saito G, Muto S, Takeda T, Date K, Fujisaka Y, Watanabe S, Fujimoto D, Uehara H, Horinaka M, Sakai T, Yano S, Tokuda S, Takayama K. Katayama Y, et al. Among authors: tamiya a. Clin Cancer Res. 2024 Nov 4. doi: 10.1158/1078-0432.CCR-24-1762. Online ahead of print. Clin Cancer Res. 2024. PMID: 39495173
Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01.
Yoshioka H, Ishida T, Atagi S, Tamiya A, Nishimura T, Iwamoto Y, Kanehara M, Kim YH, Korogi Y, Tomii K, Katakami N, Komuta K, Nishikawa M, Gemma A, Yamaki K, Kawahara M, Miyakoshi C, Mio T. Yoshioka H, et al. Among authors: tamiya a. Clin Lung Cancer. 2025 Jan;26(1):1-8. doi: 10.1016/j.cllc.2024.09.004. Epub 2024 Oct 1. Clin Lung Cancer. 2025. PMID: 39482146 Clinical Trial.
132 results